Processing

Please wait...

Settings

Settings

Goto Application

1. EP1073676 - IMMUNODIAGNOSTIC REAGENT FOR THE DETECTION OF MAEDI-VISNA VIRUS AND CAEV INFECTION

Office European Patent Office
Application Number 99920785
Application Date 26.04.1999
Publication Number 1073676
Publication Date 07.02.2001
Publication Kind B1
IPC
G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
C07K 14/155
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
C07K 14/155
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
G01N 33/531
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
G01N 33/531
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
CPC
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
C12N 2740/15022
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2740Reverse Transcribing RNA Viruses
00011Reverse Transcribing RNA Viruses
10011Retroviridae
15011Lentivirus, not HIV, e.g. FIV, SIV
15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
G01N 33/531
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
531Production of immunochemical test materials
G01N 33/56988
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
56983Viruses
56988AIDS or HTLV
Applicants INNOGENETICS NV
Inventors GONZALEZ LORENZO
TOLARI FRANCESCO
WATT NEIL
HARKISS GORDON
AMORENA BEATRIZ
SAMAN ERIC
VAN EYNDE GEERTRUI
BADIOLA DIEZ JUAN JOSE
EXTRAMIANA BELEN
BOLLO ENRICO
JUSTE RAMON A
Priority Data 98870101 30.04.1998 EP
9902810 26.04.1999 EP
Title
(DE) IMMUNODIAGNOSTISCHER WIRKSTOFF ZUM NACHWEISS VON MAEDI-VISNA VIRUS UND CAEV INFEKTIONEN
(EN) IMMUNODIAGNOSTIC REAGENT FOR THE DETECTION OF MAEDI-VISNA VIRUS AND CAEV INFECTION
(FR) REACTIF D'IMMUNODIAGNOSTIC POUR LA DETECTION D'UNE INFECTION PAR LE VIRUS MAEDI-VISNA ET LE VIRUS ARTHRITE-ENCEPHALITE CAPRINE
Abstract
(EN)
The current invention relates to a biotinylated peptide represented by the following formula: [B1 -L1] - (a) - CWHYX9X10YC- (b) - [L2- B2] (SEQ ID NO 83) wherein B represents a biotinyl moiety and L represents an amide bond or an amino acid linker sequence containing from 1 to 5 amino acid residues, with either [B1 -L1] or [L2 -B2] present or both, and wherein (a) represents from none to the maximum number of contiguous amino acids located from position 1 to position 4 in the sequence represented by SEQ ID NO 12, and wherein (b) represents from none to the maximum number of contiguous amino acids located from position 13 to position 18 in the sequence represented by SEQ ID NO 12.

(FR)
L'invention concerne un peptide biotinylé représenté par la formule générale [B1 -L1] - (a) - CWHYX9X10YC- (b) - [L2- B2] (identificateur de séquence SEQ ID N° 83), dans laquelle B est une fraction biotiynle et L est une liaison amide ou une séquence de liaison d'acides aminés contenant entre 1 et 5 résidus d'acides aminés, avec la présence de [B1 -L1] ou de [L2- B2] ou des deux à la fois. Par ailleurs, dans ladite formule, (a) est un nombre d'acides aminés contigus allant de zéro au maximum, ces résidus ayant un emplacement qui va de la position 1 à la position 4 dans la séquence représentée par l'identificateur de séquence SEQ ID N° 12, et (b) est un nombre d'acides aminés contigus allant de zéro au maximum, ces résidus ayant un emplacement qui va de la position 13 à la position 18 dans la séquence représentée par l'identificateur de séquence SEQ ID N° 12.